Barclays PLC reaffirmed their overweight rating on shares of AstraZeneca plc (LON:AZN) in a research report report published on Thursday morning. Barclays PLC currently has a GBX 6,300 ($83.57) price objective on the biopharmaceutical company’s stock.

A number of other equities analysts have also recently weighed in on the company. Citigroup Inc. reiterated a buy rating and set a GBX 6,000 ($79.59) price target on shares of AstraZeneca plc in a report on Thursday, July 13th. Liberum Capital restated a buy rating and set a GBX 4,800 ($63.67) target price on shares of AstraZeneca plc in a report on Tuesday, September 5th. Deutsche Bank AG restated a buy rating and set a GBX 5,700 ($75.61) target price on shares of AstraZeneca plc in a report on Friday, June 30th. Natixis upgraded AstraZeneca plc from a neutral rating to a buy rating and raised their target price for the company from GBX 5,000 ($66.32) to GBX 5,738 ($76.11) in a report on Wednesday, September 6th. Finally, HSBC Holdings plc cut AstraZeneca plc to a reduce rating and set a GBX 4,500 ($59.69) target price for the company. in a report on Tuesday, July 4th. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and eleven have given a buy rating to the stock. The company presently has an average rating of Hold and an average target price of GBX 5,111.27 ($67.80).

Shares of AstraZeneca plc (LON AZN) opened at 5154.00 on Thursday. AstraZeneca plc has a 52-week low of GBX 3,996.00 and a 52-week high of GBX 5,520.00. The stock’s 50 day moving average price is GBX 4,738.46 and its 200 day moving average price is GBX 4,897.65. The company’s market capitalization is GBX 65.25 billion.

COPYRIGHT VIOLATION WARNING: “AstraZeneca plc’s (AZN) “Overweight” Rating Reiterated at Barclays PLC” was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another site, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this article can be read at https://www.watchlistnews.com/astrazeneca-plcs-azn-overweight-rating-reiterated-at-barclays-plc/1617031.html.

The firm also recently announced a dividend, which was paid on Monday, September 11th. Stockholders of record on Thursday, August 10th were given a dividend of GBX 68.90 ($0.91) per share. This represents a dividend yield of 1.35%. The ex-dividend date was Thursday, August 10th.

In other news, insider Nazneen Rahman purchased 39 shares of the business’s stock in a transaction on Thursday, July 27th. The shares were bought at an average price of GBX 4,370 ($57.97) per share, with a total value of £1,704.30 ($2,260.64).

AstraZeneca plc Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with Analyst Ratings Network's FREE daily email newsletter.